Marksans Pharma has reported results for third quarter ended December 31, 2016.
The company has reported 39.67% fall in its net profit at Rs 8.44 crore for the quarter under review as compared to Rs 13.99 crore for the same quarter in the previous year. Total income of the company decreased by 6.81% at Rs 64.58 crore for the quarter under review as compared Rs 69.30 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported 36.98% fall in its net profit after taxes, minority interest and share of profit of associates at Rs 11.30 crore for the quarter ended December 31, 2016, as compared to Rs 17.93 crore for the same quarter in the previous year. Total income of the company decreased by 1.04% at Rs 215.25 crore for the quarter under review as compared Rs 217.51 crore for the corresponding quarter previous year.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: